3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Conditions
Precancerous Conditions
55
Multiple Myeloma
10
Lymphoma
10
Leukemia
10
Neoplasms, Plasma Cell
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Myeloproliferative Disorders
8
Myelodysplastic Syndromes
8
Monoclonal Gammopathy of Undetermined Significance
8
Lymphoma, T-Cell, Cutaneous
8
Lymphoma, Non-Hodgkin
8
Lymphoma, Mantle-Cell
8
Lymphoma, Large-Cell, Immunoblastic
8
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma, Follicular
8
Lymphoma, B-Cell, Marginal Zone
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Hodgkin Disease
8
Burkitt Lymphoma
8
Primary Myelofibrosis
7
Myelodysplastic-Myeloproliferative Diseases
7
Lymphoma, Large-Cell, Anaplastic
7
Leukemia, Myeloid, Acute
7
Keratosis, Actinic
7
Immunoblastic Lymphadenopathy
7
Waldenstrom Macroglobulinemia
6
Thrombocythemia, Essential
6
Sezary Syndrome
6
Mycosis Fungoides
6
Interventions
Psychotherapy
1
Psilocybin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Hospice
×
Other neoplasm
×
Clear all
NCT04950608
2026-02-17
PATH
Dana-Farber Cancer Institute
Phase 2
Completed
15 enrolled
26 charts